Home / Clinical Laboratory / Clinical Analyzer Calibrators and Reagents / Reagents / Reagent / Reagent Atellica® IM Cancer Her-2/neu (H2n) For Atellica® IM Analyzer 50 Tests 2.5 mL, 12.5 mL10995591
Picture of Reagent Atellica® IM Cancer Her-2/neu (H2n) For Atellica® IM Analyzer 50 Tests 2.5 mL, 12.5 mL10995591

Reagent Atellica® IM Cancer Her-2/neu (H2n) For Atellica® IM Analyzer 50 Tests 2.5 mL, 12.5 mL10995591

Reagent-Atellica®-IM-Cancer-Her-2-neu-(H2n)-For-Atellica®-IM-Analyzer-50-Tests-2-5-mL,-12-5-mL10995591

SKU #

#1109092

MPN #

10995591

Brand

Siemens

Stock

In Stock

Quantity

100

Features

REAGENT, IMMUNOASSAY ATELLICA H2N (50TESTS) D/S

$3,306.04 USD

Attribute Name Attribute Value
McKesson # 1109092
Manufacturer # 10995591
Brand Atellica® IM
Manufacturer Siemens
Application Reagent
For Use With For Atellica® IM Analyzer
Form Liquid
Number of Tests 50 Tests
Sample Type Human Serum Sample
Storage Requirements Requires Refrigeration
Test Name Her-2/neu (H2n)
Test Type Cancer
Type Chemiluminescent Immunoassay
UNSPSC Code 41116004
Volume 2.5 mL, 12.5 mL

Similar Items

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

Underarm Crutches McKesson Aluminum Frame Tall Adult 350 lbs. Weight Capacity Push Button - Adjustment

One Size Fits Most White NonSterile Not Rated 8211

In Stock

PR/1 $9.76 USD

  • The Atellica™ IM Her‑2/neu (H2n) assay is for in vitro diagnostic use in the quantitative determination of the HER‑2/neu protein in human serum using the Atellica™ IM Analyzer
  • HER‑2/neu values obtained may be used in the follow-up and monitoring of patients with metastatic breast cancer whose initial serum HER‑2/neu level is > 15 ng/mL
  • The clinical utility of the measurement of HER‑2/neu in serum as a prognostic indicator for early recurrence and in the management of patients on immunotherapy has not been fully established